The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai (Q36565628)
Jump to navigation
Jump to search
scientific article published on 8 January 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai |
scientific article published on 8 January 2013 |
Statements
1 reference
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai (English)
1 reference
Louis P Garrison
1 reference
Si-Tien Wang
1 reference
Hui Huang
1 reference
Abbie Ba-Mancini
1 reference
Hongliang Shi
1 reference
Kristina Chen
1 reference
Caroline Korves
1 reference
Ravinder Dhawan
1 reference
Andrew Cakana
1 reference
Helgi van de Velde
1 reference
Deyanira Corzo
1 reference
Mei Sheng Duh
1 reference
8 January 2013
1 reference
1 reference
27-36
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference